Correlation of Interleukin-17A and Beta-2-Microglobulin in Early Diagnosis of Patients with Hypertension Related Chronic Kidney Disease

Abstract Background: Interleukin-17A (IL-17A) plays a harmful role in the inflammation associated with hypertensive renal disease, investigation conducted to discover therapeutic strategies that specifically target this cytokine to mitigate the risk of kidney impairment generated by hypertension. Objective: To evaluate the role of IL-17A and β 2-MG, as markers of inflammation in hypertensive CKD patients and assess possible usage of these markers as a predictive index for CKD occurrence. Materials and Methods: The total number of participants are 100 participants including 35 CKD patients with hypertension, 35 CKD patients without hypertension, and 30 controls without hypertension or CKD, 48 individuals were male and 52 individuals were female, their ages ranged from 20 to 70, all study participants were evaluated with respect to serum IL-17A and β2-MG levels by enzyme-linked immune sorbent assay test. Results: The results showed a high significant differences in concentrations of IL-17A and β2-MG in study patient (CKD patients with hypertension, and CKD patients without hypertension) in comparison with the control group. Conclusion: Serum IL-17A and β2-MG can be used as markers of inflammation and predicators for early onset of CKD in hypertensive patient more accurately than routine diagnostic tests.